Abstract
Primary mediastinal B-cell lymphoma is an established subtype of non-Hodgkin Lymphoma with distinguishable histopathological and clinical features. It characteristically presents with a bulky mediastinal mass and in a younger, predominantly female population. Advanced age, high LDH levels, and poor performance status are associated with poorer prognosis. Endobronchial ultrasound-guided transbronchial needle aspiration may be a valuable tool for establishing the diagnosis. At a molecular level, it has overlapping traits with nodular sclerosis classical Hodgkin Lymphoma. There is a variety of treatment options, with no standardized regimen. The use of rituximab combined with chemotherapy has correlated with good outcomes. The use of consolidative radiotherapy is controversial, with questionable benefit and established long-term toxicity, including secondary malignancy and cardiovascular disease. An FDG-PET scan is indicated when monitoring for response, because a residual mediastinal mass is commonly seen upon treatment completion but does not always indicate active disease. Relapse usually occurs within the first year, but overall survival is similar to that for diffuse large B-cell lymphoma.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Johnson P and Davies AJ. Primary Mediastinal B-Cell Lymphoma. Am Soc Hematol. 2008.
Vassilakopoulos TP, Pangalis GA, Katsigiannis A, et al. Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone with or without Radiotherapy in Primary Mediastinal Large B-Cell Lymphoma: The Emerging Standard of Care. Oncologist. 2012;17(2):239–49. This study reported improved survival after chemotherapy combined with rituximab, and no significant difference in survival when radiotherapy was added to systemic therapy.
Savage KJ. Primary Mediastinal Large B-Cell Lymphoma. Oncologist. 2006;11(5):488–95.
Witzens-Harig M, Ho AD, Kuhnt E, et al. Primary Mediastinal B Cell Lymphoma Treated with CHOP-Like Chemotherapy with or without Rituximab: 5 Year Results of the Mabthera International Trial Group (MInT) Study [abstract]. Blood 2012;120:Abstract 1612.
Cazals-Hatem D, Lepage E, Ferrant A, et al. Primary mediastinal large B-cell lymphoma. A clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA (“Groupe d'Etude des Lymphomes de l'Adulte”) study. Am J Surg Pathol. 1996;20(7):877–88.
The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-hodgkin’s lymphoma. N Engl J Med. 1993;329(14):987–94.
Savage KJ, Al-Rajhi N, Voss N, et al. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol. 2006;17:123–30.
Zinzani PL, Martelli M, Bertini M, et al. Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. Haematologica. 2002;87:1258–64.
Swerdlow SH, Campo E, Harris NL et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Fourth Edition.
Moonim MT, Breen R, Fields PA, et al. Diagnosis and Subtyping of De Novo and Relapsed Mediastinal Lymphomas by Endobronchial Ultrasound Needle Aspiration. Am J Respir Crit Care Med. 2013;188(10):1216–23.
Senturk A, Babaoglu E, Kilic H, et al. Endobronchial ultrasound-guided transbronchial needle aspiration in the diagnosis of lymphoma. Asian Pac J Cancer Prev. 2014;15(10):4169–73.
Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198:851–62.
Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood. 2003;102:3871–9.
Hodgson DC. Late Effects in the Era of Modern Therapy for Hodgkin Lymphoma. Hematol Am Soc Hematol Educ Program. 2011;2011:323–9.
Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma. N Engl J Med. 2013;368(15):1408–16. This study reported high overall survival among patients receiving rituximab-based chemotherapy. It also suggests radiotherapy does not change overall survival.
Hamlin PA, Portlock CS, Straus DJ, et al. Primary Mediastinal Large B-Cell Lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999. Br J Haematol. 2005;130:691–9.
Todeschini G, Secchi S, Morra E, et al. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Br J Cancer. 2004;90:372–6.
Todeschini G, Ambrosetti A, Meneghini V, et al. Mediastinal large B-cell lymphoma with sclerosis: a clinical study of 21 patients. J Clin Oncol. 1990;8:804–8.
Lazzarino M, Orlandi E, Paulli M, et al. Primary mediastinal B-cell lymphoma with sclerosis: an aggressive tumor with distinctive clinical and pathologic features. J Clin Oncol. 1993;11:2306–13.
Rieger M, Osterborg A, Pettengell R, et al. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. Ann Oncol. 2011;22:664–70.
Zinzani PL, Stefoni V, Finolezzi E, et al. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study. Clin Lymphoma Myeloma. 2009;9:381–5.
Dunleavy K, Pittaluga S, Janik J, et al. Primary mediastinal large B-cell lymphoma (PMBL) outcome is significantly improved by the addition of rituximab to dose adjusted (DA)-EPOCH and overcomes the need for radiation. Blood. 2005;106:929a.
Avigdor A, Sirotkin T, Kedmi M, et al. The Impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B-cell lymphoma. Ann Hematol. 2014. This study revealed the importance of rituximab for treatment of primary mediastinal B-cell lymphoma. It also compared two different chemotherapy regimens in a retrospective analysis and reported no difference in efficacy.
De Sanctis V, Finolezzi E, Osti MF, et al. MACOP-B and involved-field radiotherapy is an effective and safe therapy for primary mediastinal large B cell lymphoma. Int J Radiat Oncol Biol Phys. 2008;72:1154–60.
Mazzarotto R, Boso C, Vianello F, et al. Primary mediastinal large B-cell lymphoma: results of intensive chemotherapy regimens (MACOP-B/VACOP-B. plus involved field radiotherapy on 53 patients. A single institution experience. Int J Radiat Oncol Biol Phys. 2007;68:823–9.
Rodriguez J, Conde E, Gutierrez A, et al. Primary mediastinal large cell lymphoma (PMBL): frontline treatment with autologous stem cell transplantation (ASCT). The GEL-TAMO experience. Hematol Oncol. 2008;26(3):171–8.
Cairoli R, Grillo G, Tedeschi A, et al. Efficacy of an early intensification treatment integrating chemotherapy, autologous stem cell transplantation and radiotherapy for poor risk primary mediastinal large B cell lymphoma with sclerosis. Bone Marrow Transplant. 2002;29:473–7.
Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using 18 F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin’s disease and non-Hodgkin’s lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood. 1999;94:429–33.
Zinzani PL, Fanti S, Battista G, et al. Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. Br J Cancer. 2004;91(5):850–4.
Zinzani PL, Martelli M, Bendandi M, et al. Primary mediastinal large B-cell lymphoma with sclerosis: a clinical study of 89 patients treated with MACOP-B chemotherapy and radiation therapy. Haematologica. 2001;86(2):187–91.
Compliance with ethics guidelines
Conflict of interest
Alev Brown and Tomoko Tagawa declare that they have no conflict of interest.
Human and animal rights and informed consent
This article does not contain any studies with human or animal subjects performed by either of the authors.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Brown, A., Tagawa, T. Primary mediastinal B-cell lymphoma. Curr Respir Care Rep 3, 187–191 (2014). https://doi.org/10.1007/s13665-014-0087-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13665-014-0087-z